0
Your cart

Your cart is empty

Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology

Buy Now

Targeting the DNA Damage Response for Anti-Cancer Therapy (Paperback, Softcover reprint of the original 1st ed. 2018) Loot Price: R5,604
Discovery Miles 56 040
Targeting the DNA Damage Response for Anti-Cancer Therapy (Paperback, Softcover reprint of the original 1st ed. 2018): John...

Targeting the DNA Damage Response for Anti-Cancer Therapy (Paperback, Softcover reprint of the original 1st ed. 2018)

John Pollard, Nicola Curtin

Series: Cancer Drug Discovery and Development

 (sign in to rate)
Loot Price R5,604 Discovery Miles 56 040 | Repayment Terms: R525 pm x 12*

Bookmark and Share

Expected to ship within 10 - 15 working days

Over the past decade a complex role for DNA damage response (DDR) in tumorigenesis has emerged. A proficient DDR has been shown to be a primary cause for cellular resistance to the very many DNA damaging drugs, and IR, that are widely used as standard-of-care across multiple cancer types. It has also been shown that defects in this network, predominantly within the ATM mediated signaling pathway, are commonly observed in cancers and may be a primary event during tumorigenesis. Such defects may promote a genomically unstable environment, facilitating the persistence of mutations, any of which may provide a growth or survival advantage to the developing tumor. In addition, these somatic defects provide opportunities to exploit a reliance on remaining repair pathways for survival, a process which has been termed synthetic lethality. As a result of all these observations there has been a great interest in targeting the DDR to provide anti-cancer agents that may have benefit as monotherapy in cancers with high background DNA damage levels or as a means to increase the efficacy of DNA damaging drugs and IR. In this book we will review a series of important topics that are of great interest to a broad range of academic, industrial and clinical researchers, including the basic science of the DDR, its role in tumorigenesis and in dictating response to DNA damaging drugs and IR. Additionally, we will focus on the several proteins that have been targeted in attempts to provide drug candidates, each of which appear to have quite distinct profiles and could represent very different opportunities to provide patient benefit.

General

Imprint: Springer Nature Switzerland AG
Country of origin: Switzerland
Series: Cancer Drug Discovery and Development
Release date: December 2018
First published: 2018
Editors: John Pollard • Nicola Curtin
Dimensions: 235 x 155 x 21mm (L x W x T)
Format: Paperback
Pages: 401
Edition: Softcover reprint of the original 1st ed. 2018
ISBN-13: 978-3-03-009336-5
Categories: Books > Medicine > Clinical & internal medicine > Gene therapy
Books > Medicine > Clinical & internal medicine > Diseases & disorders > Oncology > General
Promotions
LSN: 3-03-009336-0
Barcode: 9783030093365

Is the information for this product incomplete, wrong or inappropriate? Let us know about it.

Does this product have an incorrect or missing image? Send us a new image.

Is this product missing categories? Add more categories.

Review This Product

No reviews yet - be the first to create one!

Partners